Autolus Therapeutics (AUTL) financial statements
Autolus Therapeutics reported revenue of $75M in fiscal 2025, up 58.2% a year over 9 years.
Net income was -$288M.
Free cash flow was -$303M.
The diluted share count rose 2579% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Autolus Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $2M | $1M | $3M | — | — | — | $2M | $10M | $75M |
| Cost of revenue | — | — | — | — | — | — | — | $0 | $11M | $96M |
| Gross profit | — | — | — | — | — | — | — | $2M | -$1M | -$21M |
| Research and development | $10M | $16M | $36M | $105M | $135M | $111M | $117M | $130M | $138M | $118M |
| Selling, general and admin | $5M | $9M | $23M | $39M | $35M | $32M | $32M | $47M | $102M | $132M |
| Operating income | — | -$23M | -$58M | -$146M | -$168M | -$141M | -$143M | -$180M | -$241M | -$271M |
| Interest expense | — | — | — | $0 | $0 | $1M | $9M | $45M | $9M | $37M |
| Pre-tax income | -$14M | -$23M | -$52M | -$139M | -$166M | -$142M | -$149M | -$208M | -$219M | -$286M |
| Income tax | -$2M | -$4M | -$7M | -$15M | -$24M | $58,000 | $272,000 | -$19,000 | $2M | $2M |
| Net income | -$13M | -$20M | -$45M | -$124M | -$142M | -$142M | -$149M | -$208M | -$221M | -$288M |
| EPS (diluted) | -$1.26 | -$1.43 | -$1.42 | -$2.88 | -$2.76 | -$1.97 | -$1.57 | -$1.20 | -$0.86 | -$1.08 |
| Diluted shares | 10M | 14M | 32M | 43M | 52M | 72M | 95M | 174M | 255M | 266M |
| Gross margin | — | — | — | — | — | — | — | 100.0% | -12.5% | -27.8% |
| Operating margin | — | -1383.2% | -4089.1% | -5022.8% | — | — | — | -10583.1% | -2385.6% | -358.9% |
| Net margin | -1035.5% | -1165.2% | -3180.6% | -4258.9% | — | — | — | -12272.3% | -2180.5% | -381.4% |
Balance sheet
Fiscal years, from Autolus Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $28M | $137M | $247M | $211M | $153M | $310M | $382M | $240M | $588M | $301M |
| Receivables | — | — | — | — | — | $0 | $121,000 | $109,000 | $15,000 | $24M |
| Inventory | — | — | — | — | — | — | — | $0 | $4M | $33M |
| Total current assets | — | $142M | $259M | $249M | $197M | $347M | $426M | $275M | $661M | $436M |
| Property, plant and equipment | — | $6M | $14M | $28M | $38M | $34M | $35M | $35M | $50M | $64M |
| Total assets | — | $149M | $273M | $304M | $294M | $406M | $490M | $375M | $783M | $589M |
| Total current liabilities | — | $5M | $17M | $25M | $34M | $29M | $46M | $45M | $61M | $73M |
| Long-term debt | — | $763,000 | $380,000 | $0 | — | — | — | — | — | — |
| Total liabilities | — | $6M | $18M | $49M | $84M | $92M | $192M | $264M | $355M | $411M |
| Shareholders' equity | $31M | $143M | $255M | $255M | $210M | $313M | $299M | $111M | $427M | $178M |
| Net debt | -$28M | -$136M | -$247M | -$211M | -$153M | -$310M | -$382M | -$240M | -$227M | -$104M |
Cash flow
Fiscal years, from Autolus Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10M | -$16M | -$32M | -$101M | -$118M | -$118M | -$112M | -$146M | -$206M | -$284M |
| Capital spending | $2M | $3M | $9M | $18M | $15M | $9M | $11M | $11M | $22M | $19M |
| Free cash flow | -$12M | -$19M | -$41M | -$120M | -$132M | -$127M | -$123M | -$157M | -$228M | -$303M |
| Stock-based compensation | $2M | $3M | $7M | $30M | $20M | $10M | $12M | $11M | $15M | $14M |
| Free cash flow margin | -965.7% | -1136.2% | -2889.6% | -4120.5% | — | — | — | -9221.0% | -2256.4% | -401.4% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AUTL.
Open AUTL in InvestinglyQuestions
What was Autolus Therapeutics's revenue in 2025?
$75M in fiscal 2025, from its 10-K filing.
How much free cash flow does Autolus Therapeutics generate?
-$303M in fiscal 2025 (operating cash flow minus capital spending).
From Autolus Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.